Literature DB >> 8835349

Hepatitis C genotypes in patients with dual hepatitis B and C virus infection.

P Pontisso1, M Gerotto, M G Ruvoletto, G Fattovich, L Chemello, S Tisminetzky, F Baralle, A Alberti.   

Abstract

In patients with chronic hepatitis B and C virus (HBV, HCV) infection, an inverse relationship in the replicative activity of the two viruses has been reported. In the present study the genotype of HCV was evaluated in 34 consecutive cases found with hepatitis B surface antigen (HBsAg) and anti-HCV in the serum, in order to identify its possible influence in determining the pattern of HBV/HCV interaction. Nineteen patients were HCV-RNA positive and could be genotyped: 8 were infected by HCV-1 (3 by HCV-1a and 5 by HCV-1b), 10 by HCV-2, and only 1 by HCV-3. Among these, 3 were HBV-DNA positive, compared to 10 of 15 HCV-RNA-negative patients (P = 0.003), and all 3 were coinfected with HCV-2. Mean alanine aminotransferase (ALT) levels were similar between patients infected with HCV-1 and HCV-2. Among 7 patients with cirrhosis 5 were infected by HCV-2, while 6 of 12 of those without cirrhosis had HCV-1 infection. In conclusion, HBV replication was inhibited more efficiently by HCV-1 than by HCV-2. Cirrhosis was frequently found in patients with dual HBV and HCV-2 infection.

Entities:  

Mesh:

Year:  1996        PMID: 8835349     DOI: 10.1002/(SICI)1096-9071(199602)48:2<157::AID-JMV7>3.0.CO;2-8

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 2.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

3.  Dual chronic hepatitis B virus and hepatitis C virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2009-08-08       Impact factor: 6.047

4.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

5.  Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia, North Africa.

Authors:  Samar Ben Halima; Olfa Bahri; Nadia Maamouri; Imed Cheikh; Nissaf Ben Alaya; Amel Sadraoui; Ons Azaiez; Msaddak Azouz; Nabyl Ben Mami; Henda Triki
Journal:  Virol J       Date:  2010-09-15       Impact factor: 4.099

Review 6.  Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.

Authors:  Yun-Fan Liaw
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

Review 7.  Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.

Authors:  Seth D Crockett; Emmet B Keeffe
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-13       Impact factor: 3.944

8.  Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin.

Authors:  Janine Hartl; Claudia Ott; Gabriele Kirchner; Bernd Salzberger; Reiner Wiest
Journal:  Clin Pract       Date:  2012-07-10

Review 9.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.

Authors:  Dimitris Konstantinou; Melanie Deutsch
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

Review 10.  The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.

Authors:  Jun-Ying Liu; Yun-Jian Sheng; Huai-Dong Hu; Qing Zhong; Jing Wang; Shi-Wen Tong; Zhi Zhou; Da-Zhi Zhang; Peng Hu; Hong Ren
Journal:  Virol J       Date:  2012-09-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.